Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019188 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00019188: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019188 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019188, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients with AIDS -related Kaposi's sarcoma.
Interventions
- DRUG interleukin-12
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
What the finished NCT00019188 record still lists
NCT00019188 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which interleukin-12 is the first listed.
NCT00019188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019188 about?
NCT00019188 is a clinical study titled "Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma". RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients with AIDS -related Kaposi's sarcoma.
What is the current status of trial NCT00019188?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00019188?
The interventions under investigation include: interleukin-12 (DRUG).
Who is sponsoring clinical trial NCT00019188?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia